REDWOOD CITY, Calif., April 10 /PRNewswire-FirstCall/ -- Maxygen, Inc. will host a presentation at 8:00 a.m. EDT on Tuesday, April 17, 2007, to review its development program for MAXY-G34, Maxygen’s next- generation G-CSF drug for the treatment of neutropenia. The company plans to summarize its Phase I clinical results, review high-level development plans, and provide an overview of the patent landscape of MAXY-G34.
Russell Howard, Chief Executive Officer of Maxygen, will host the presentation. Elliot Goldstein, Chief Operating Officer, Santosh Vetticaden, Chief Medical Officer, Stuart Pollard, Chief Scientific Officer, and Michael Rabson, General Counsel, will also participate. Investors interested in attending the live presentation can contact michele.boudreau@maxygen.com for details.
Participants in the U.S. can access the call by dialing 800.310.7032. International participants can dial 719.457.2694. A telephone replay of the conference call will be available until May 17, 2007. To access the replay, please call 888.203.1112 (U.S.) or 719.457.0820 (international) and use the passcode 4219250.
A live webcast of the conference call, together with additional presentation materials, will be available in the “Investors” section of the Maxygen web site at www.maxygen.com. An archived version of the webcast will be available until May 17, 2007, in the “Investors” section of the Maxygen website at www.maxygen.com.
About Maxygen
Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. We look for opportunities where our proprietary protein modification technologies can address significant therapeutic needs. Products developed by Maxygen now in clinical trials include a novel G-CSF for the treatment of neutropenia and a novel interferon-alpha for the treatment of hepatitis C virus (HCV) infection. Maxygen’s approach may allow us to leverage the established development and regulatory paths of approved drugs. We believe this advantage may translate to a greater chance of successfully bringing important new drugs to market. www.maxygen.com
Maxygen, Inc.
CONTACT: Michele Boudreau, Investor and Public Relations of Maxygen,+1-650-279-2088
Web site: http://www.maxygen.com//
